Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
详细信息 查看全文
- 作者：Susan M. Domcheka ; susan.domchek@uphs.upenn.edu" class="auth_mail" title="E-mail the corresponding author ; Carol Aghajanianb ; Ronnie Shapira-Frommerc ; Rita K. Schmutzlerd ; M. William Audehe ; Michael Friedlanderf ; Judith Balmañ ; ag ; Gillian Mitchellh ; i ; Georgeta Friedj ; Salomon M. Stemmerk ; Ayala Hubertl ; m ; Ora Rosengartenn ; Niklas Lomano ; Jane D. Robertsonp ; 1 ; Helen Mannp ; Bella Kaufmanc
- 关键词：Olaparib ; Ovarian cancer ; BRCA1/2 mutation ; Phase II
- 刊名：Gynecologic Oncology
- 出版年：2016
- 出版时间：February 2016
- 年：2016
- 卷：140
- 期：2
- 页码：199-203
- 全文大小：274 K
文摘
- •
Women with BRCA1/2m ovarian cancer and > 3 chemotherapy regimens had clinical benefit from olaparib
- •
Response rate was higher for patients with platinum-sensitive versus platinum-resistant tumors
- •
Duration of response was similar for platinum-sensitive versus platinum-resistant tumors
- •
No new safety findings were identified in this heavily pretreated population
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |